2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1571

Musculoskeletal Complaints and Psoriatic Arthritis in Primary Care Patients with Psoriasis
Abstract Number: 1060

Musculoskeletal Surgeries and Procedures in Patients with RA: Results from a UK Retrospective Study
Abstract Number: 153

Musculoskeletal Ultrasound of Finger and Foot Joints in a Population of Volunteers: Is Osteoarthritis an Underestimated Problem? Results from the German “Rheuma-Truck” Cohort
Abstract Number: 183

Musculoskeletal Ultrasound Reveals Calcific Deposition Arthropathy in Seronegative Inflammatory Arthritis Patients
Abstract Number: 312

Mutations in the MTHFR Gene Are Not Associated with Methotrexate Intolerance in Patients with Juvenile Idiopathic Arthritis
Abstract Number: 321

Mutations of Familial Hemophagocytic Lymphohistiocytosis (FHL) Related Genes and Abnormalities of Cytotoxicity function tests in Patients with Macrophage Activation Syndrome (MAS) Occurring in Systemic Juvenile Idiopathic Arthritis (sJIA)
Abstract Number: 1931

Mycophenolate Mofetil (MMF) Use in Scleroderma Patients with Pulmonary Hypertension: Observations from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Cohort
Abstract Number: 2766

Mycophenolate Mofetil in the Treatment of Primary Central Nervous System Vasculitis
Abstract Number: 1682

Mycophenolate Mofetil Versus Azathioprine in Scleroderma-Associated Interstitial Lung Disease: Results from the Australian Scleroderma Cohort Study
Abstract Number: 1644

Mycophenolic Acid and Ribavirin Induces Cytoplasmic Autoimmunogenic Rods and Rings Structures in Vivo
Abstract Number: 317

Myeloid Related Proteins 8 and 14 (MRP 8/14) – Potential Biomarkers of Disease Activity of Arthritis in Children with Trisomy 21
Abstract Number: 2165

Myeloid-Derived Suppressor Cells in Rheumatoid Arthritis: Friend or Foe?
Abstract Number: 554

Myocardial Infarction Risk with Diclofenac Use in Spondyloarthropathy Versus Non-Inflammatory Low Back Pain
Abstract Number: 1271

Myocarditis in Antisynthetase Syndrome
Abstract Number: 1272

Myositis-Specific and Myositis Associated Autoantibodies in Indian Patients with Inflammatory Myositis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].